Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition.
- DOI
- 10.1016/j.isci.2026.116772
- Published
- 2026 Aug 21
- Container
- iScience
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.isci.2026.116772,
title = {Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition.},
author = {Botta GP and Edwards W and Nishizaki D and Hargreaves DC and Kato S and Kurzrock R},
year = {2026},
journal = {iScience},
doi = {10.1016/j.isci.2026.116772},
url = {https://doi.org/10.1016/j.isci.2026.116772}
}RIS
TY - JOUR TI - Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition. AU - Botta GP AU - Edwards W AU - Nishizaki D AU - Hargreaves DC AU - Kato S AU - Kurzrock R PY - 2026 JO - iScience DO - 10.1016/j.isci.2026.116772 UR - https://doi.org/10.1016/j.isci.2026.116772 ER -
APA
GP, B., W, E., D, N., DC, H., S, K., & R, K. (2026). Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition.. iScience. https://doi.org/10.1016/j.isci.2026.116772
Source records
- pubmed · retrieved 2026-09-26T13:32:45.909Z